Merus N.V.
Subsidiary of Genmab (GMAB)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Zenocutuzumab(Bizengri) | Approved | HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody | Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma Cholangiocarcinoma |
| Phase 2 | EGFR x c-METMultispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2028 (2)
2029 (1)
February 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (13)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $12M | $80M | $367M | $96M | report ↗ |
View 12 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $8.8M | $94M | $444M | $158M | report ↗ |
| 2025-Q1 | $26M | $80M | $198M | $96M | report ↗ |
| 2024-Q3 | $12M | $63M | $434M | $100M | report ↗ |
| 2024-Q2 | $7.3M | $49M | $630M | $50M | report ↗ |
| 2024-Q1 | $7.9M | $39M | $179M | $34M | report ↗ |
| 2023-Q3 | $11M | $37M | $243M | $23M | report ↗ |
| 2023-Q2 | $10M | $28M | $102M | $32M | report ↗ |
| 2023-Q1 | $14M | $35M | $103M | $40M | report ↗ |
| 2022-Q3 | $6.6M | $42M | $192M | $25M | report ↗ |
| 2022-Q2 | $13M | $31M | $215M | $5.7M | report ↗ |
| 2022-Q1 | $12M | $27M | $195M | $19M | report ↗ |
| 2021-Q3 | $14M | $26M | $159M | $15M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $36M | $225M | $293M | $215M | report ↗ |
Merus N.V. reported revenue of $36.133M, down 17.8% YoY, R&D spend of $225.368M, up 60.2% YoY, cash and equivalents of $293.294M, and a quarterly net burn of $215.326M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text